Menu
Home Explore People Places Arts History Plants & Animals Science Life & Culture Technology
On this page
Tideglusib
Chemical compound

Tideglusib (NP-12, NP031112) is a potent and irreversible small molecule glycogen synthase kinase 3 (GSK-3) inhibitor.

Related Image Collections Add Image
Profiles
1 Image
We don't have any YouTube videos related to Tideglusib yet.
We don't have any PDF documents related to Tideglusib yet.
We don't have any Books related to Tideglusib yet.
We don't have any archived web articles related to Tideglusib yet.

Clinical trials

Tideglusib has been evaluated in clinical trials for:

Research

Tideglusib is or has been under investigation for multiple applications:

  • Tooth repair mechanisms that promotes dentine reinforcement of a sponge structure until the sponge biodegrades, leaving a solid dentine structure. In 2016, the results of animal studies were reported in which 0.14 mm holes in mouse teeth were permanently filled.910
  • Preclinical in vitro studies were carried out for neuroblastoma and ovarian cancer with significant ROS-induced apoptosis.1112
  • Arrhythmogenic Right Ventricular Cardiomyopathy as of 2025.13

References

  1. Domínguez JM, Fuertes A, Orozco L, del Monte-Millán M, Delgado E, Medina M (January 2012). "Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib". The Journal of Biological Chemistry. 287 (2): 893–904. doi:10.1074/jbc.M111.306472. PMC 3256883. PMID 22102280. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256883 ↩

  2. Mathuram TL, Reece LM, Cherian KM (August 2018). "GSK-3 Inhibitors: A Double-Edged Sword? - An Update on Tideglusib". Drug Research. 68 (8): 436–443. doi:10.1055/s-0044-100186. PMID 29388174. /wiki/Doi_(identifier) ↩

  3. Del Ser T (2010). "Phase IIa clinical trial on Alzheimer's disease with NP12, a GSK3 inhibitor". Alzheimer's & Dementia. 6 (4): S147. doi:10.1016/j.jalz.2010.05.455. S2CID 54293332. /wiki/Doi_(identifier) ↩

  4. Eldar-Finkelman H, Martinez A (2011). "GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS". Frontiers in Molecular Neuroscience. 4: 32. doi:10.3389/fnmol.2011.00032. PMC 3204427. PMID 22065134. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204427 ↩

  5. del Ser T, Steinwachs KC, Gertz HJ, Andrés MV, Gómez-Carrillo B, Medina M, et al. (2013). "Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study". Journal of Alzheimer's Disease. 33 (1): 205–215. doi:10.3233/JAD-2012-120805. PMID 22936007. S2CID 21892732. /wiki/Doi_(identifier) ↩

  6. "FDA Grants Fast Track Status to Tideglusib (ZentylorTM) for Progressive Supranuclear Palsy". PR Newswire Europe Including UK Disclose. 10 September 2010. ProQuest 750175748. https://www.prnewswire.com/news-releases/fda-grants-fast-track-status-to-tideglusib-zentylortm-for-progressive-supranuclear-palsy-102561614.html ↩

  7. Domínguez JM, Fuertes A, Orozco L, del Monte-Millán M, Delgado E, Medina M (January 2012). "Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib". The Journal of Biological Chemistry. 287 (2): 893–904. doi:10.1074/jbc.M111.306472. PMC 3256883. PMID 22102280. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256883 ↩

  8. "AMO-2". AMO Pharmaceuticals. Retrieved 2017-09-21. http://www.amo-pharma.com/amo_02.htm ↩

  9. Neves VC, Babb R, Chandrasekaran D, Sharpe PT (January 2017). "Promotion of natural tooth repair by small molecule GSK3 antagonists". Scientific Reports. 7: 39654. Bibcode:2017NatSR...739654N. doi:10.1038/srep39654. PMC 5220443. PMID 28067250. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220443 ↩

  10. Gallagher J (2017-01-09). "'Tooth repair drug' may replace fillings". BBC News. Retrieved 2017-01-09. https://www.bbc.co.uk/news/uk-38524566 ↩

  11. Mathuram TL, Ravikumar V, Reece LM, Sasikumar CS, Cherian KM (2017). "Correlative Studies Unravelling the Possible Mechanism of Cell Death in Tideglusib-Treated Human Ovarian Teratocarcinoma-Derived PA-1 Cells". Journal of Environmental Pathology, Toxicology and Oncology. 36 (4): 321–344. doi:10.1615/JEnvironPatholToxicolOncol.2017025018. PMID 29431064. /wiki/Doi_(identifier) ↩

  12. Mathuram TL, Ravikumar V, Reece LM, Karthik S, Sasikumar CS, Cherian KM (September 2016). "Tideglusib induces apoptosis in human neuroblastoma IMR32 cells, provoking sub-G0/G1 accumulation and ROS generation". Environmental Toxicology and Pharmacology. 46: 194–205. doi:10.1016/j.etap.2016.07.013. PMID 27490211. /wiki/Doi_(identifier) ↩

  13. https://www.phri.ca/research/target-2/ https://www.phri.ca/research/target-2/ ↩